Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Did GSK's Nucala Trials In COPD Strengthen Confidence In The Eosinophil Biomarker?

Aug 01 2018

• By Derrick Gingery

White blood cells in peripheral blood smear, Wright stain

Related Content

GSK's Nucala For COPD Needs Better-Defined Patient Population, US FDA Panel Says

Jul 26 2018

GSK's Nucala For COPD Faces Questions On Efficacy Results, Missing Data

Jul 23 2018

Birth Of A Biomarker? FDA Doesn't Define Eosinophilic Asthma, Defers To Docs On Nucala

Mar 21 2016

Glaxo Set To File Nucala In COPD, Despite Mixed Phase III Results

Sep 13 2017

Related Companies

GSK plc

Additional Topics

Advisory Committees Regulation FDA Respiratory BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window